版本:
中国

BRIEF-Miragen Therapeutics presents interim results from mrg-201 phase 1 clinical trial

April 27 Miragen Therapeutics Inc:

* Miragen Therapeutics presents interim results from mrg-201 phase 1 clinical trial demonstrating pharmacodynamic activity in human skin incisions

* Miragen Therapeutics Inc says mrg-201 has been generally well-tolerated in volunteers

* Miragen Therapeutics Inc says findings support further investigation of mrg-201 as a novel therapeutic for fibrotic diseases Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐